Today: September 26, 2018, 6:36 am
  
Health

Grant programme for publications of oncolytic virotherapy announced

Grant programme announcement The International Virotherapy Center announces a grant programme for publication of prospective or retrospective clinical research, and case reports on oncolytic virotherapy with Rigvir.
Oncolytic virotherapy
Oncolytic virotherapy
PR-Inside.com: 2016-07-05 12:37:41
Grant programme announcement

The International Virotherapy Center announces a grant programme for publication of prospective or retrospective clinical research, and case reports on oncolytic virotherapy.

1. The grant programme up to a maximum of 3000 EUR for publication of prospective or retrospective clinical research, and case reports on oncolytic virotherapy in a Pubmed indexed journal.


2. The grant programme to a maximum of 1000 EUR for publication of prospective or retrospective clinical research, and case reports on oncolytic virotherapy in a popular science journal.

Competition rules:

The grant application is open for all scientists except employees of the IVC and related organizations.

The grant is awarded after publication of the respective manuscript.

The research described should be about the use of Rigvir, not the use of Rigvir in combination with other drugs, food supplements etc.

Applicants are encouraged to apply for an early opinion on feasibility of the project; a draft manuscript should be provided prior to submission to a journal.

Applications and draft manuscript files not larger than 10 MB should be sent to: peteris@virotherapy.eu

The International Virotherapy Center (IVC) was founded to co-ordinate and promote oncolytic virotherapy worldwide. The mission of the IVC is to provide cancer virotherapy to every patient who would benefit from it. One of the most important objectives of IVC is to support research in the oncolytic virotherapy field and to establish the knowledge base for the practical use of oncolytic virotherapy.

Oncolytic virotherapy is cancer treatment with a specific virus which entering the human body is able to find and destroy malignant tumour cells. Rigvir has been approved for treatment of melanoma; however, in clinical practice it has been widely used for treatment of several other malignant tumours. Since 2015, Rigvir has been included in clinical guidelines approved by the Latvian National Health Service. Meanwhile, the patients from countries, where this medicine has not yet been approved, may receive the virotherapy with Rigvir as medical tourists. Currently, cancer patients from over 50 countries have already received virotherapy with Rigvir.

Press Information
International Virotherapy Center
Teatra 9, Riga

LV-1050

Latvia

Valdis Točs
Head of Communications
+371 26159666
email
www.rigvir.com


# 358 Words
Related Articles
 
More From Health
NSAV SUBSIDIARY SIGNS MAJOR AGREEMENT WITH ELI [..]
Net Savings Link, Inc. (OTC: NSAV), a medical technology and software company, announced today that its subsidiary, Shanghai based [..]
Cadrock Secures US$5m for Therapy Targeting $35 [..]
- Enrolls first clinical trial patients in Sydney, Australia SYDNEY, Sept 4, 2018 - (ACN Newswire) - Cadrock Pty Ltd, [..]
NEGTEC launches Crowdfunding Portal promoting Regenerative Medicine
Dream-Kicker.com to offer donation-based, cryptocurrency support for cutting-edge regenerative medicine and medical equipment TOKYO, [..]
NSAV ANNOUNCES AGREEMENT TO ACQUIRE MAJOR STAKE [..]
Net Savings Link, Inc. (OTC: NSAV), a medical technology and software company, announced today that the Company has acquired a [..]
Novotech the Asia-Pacific CRO named Top 10 [..]
SYDNEY, Aug 23, 2018 - (ACN Newswire) - Asia-Pacific specialist CRO Novotech has been selected as one of the Top [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.